Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France

Archive ouverte

Oussalah, Abderrahim | Gleye, Stanislas | Clerc-Urmès, Isabelle | Laugel, Elodie | Callet, Jonas | Barbé, Françoise | Orlowski, Sophie | Malaplate-Armand, Catherine | Aimone-Gastin, Isabelle | Fofou-Caillierez, Ma’atem Béatrice | Merten, Marc | Jeannesson, Élise | Kormann, Raphaël | Olivier, Jean-Luc | Guéant-Rodriguez, Rosa-Maria | Namour, Fares | Bevilacqua, Sybille | Losser, Marie-Reine | Levy, Bruno | Kimmoun, Antoine | Gibot, Sébastien | Thilly, Nathalie | Frimat, Luc | Schvoerer, Evelyne | Guéant, Jean-Louis

Edité par CCSD ; Oxford University Press (OUP) -

International audience. Background: In patients with severe coronavirus disease 2019 (COVID-19), data are scarce and conflicting regarding whether chronic use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) influences disease outcomes. In patients with severe COVID-19, we assessed the association between chronic ACEI/ARB use and the occurrence of kidney, lung, heart, and liver dysfunctions and the severity of the inflammatory reaction as evaluated by biomarkers kinetics, and their association with disease outcomes.Methods: We performed a retrospective longitudinal cohort study on consecutive patients with newly diagnosed severe COVID-19. Independent predictors were assessed through receiver operating characteristic analysis, time-series analysis, logistic regression analysis, and multilevel modeling for repeated measures.Results: On the 149 patients included in the study 30% (44/149) were treated with ACEI/ARB. ACEI/ARB use was independently associated with the following biochemical variations: phosphorus >40 mg/L (odds ratio [OR], 3.35, 95% confidence interval [CI], 1.83-6.14), creatinine >10.1 mg/L (OR, 3.22, 2.28-4.54), and urea nitrogen (UN) >0.52 g/L (OR, 2.65, 95% CI, 1.89-3.73). ACEI/ARB use was independently associated with acute kidney injury stage ≥1 (OR, 3.28, 95% CI, 2.17-4.94). The daily dose of ACEI/ARB was independently associated with altered kidney markers with an increased risk of +25 to +31% per each 10 mg increment of lisinopril-dose equivalent. In multivariable multilevel modeling, UN >0.52 g/L was independently associated with the risk of acute respiratory failure (OR, 3.54, 95% CI, 1.05-11.96).Conclusions: Patients chronically treated with ACEI/ARB who have severe COVID-19 are at increased risk of acute kidney injury. In these patients, the increase in UN associated with ACEI/ARB use could predict the development of acute respiratory failure.

Consulter en ligne

Suggestions

Du même auteur

The spectrum of biochemical alterations associated with organ dysfunction and inflammatory status and their association with disease outcomes in severe COVID-19: A longitudinal cohort and time-series design study

Archive ouverte | Oussalah, Abderrahim | CCSD

International audience. Background: In patients with severe COVID-19, no data are available on the longitudinal evolution of biochemical abnormalities and their ability to predict disease outcomes.Methods: Using a r...

Coronavirus disease 2019: acute Fanconi syndrome precedes acute kidney injury

Archive ouverte | Kormann, Raphaël | CCSD

International audience. BackgroundRecent data have shown that severe acute respiratory syndrome coronavirus 2 can infect renal proximal tubular cells via Angiotensin Converting Enzyme 2 (ACE2) . Our objective was to...

Newborn screening of phenylketonuria in France. Le dépistage de la phénylcétonurie en France

Archive ouverte | Wiedemann, Arnaud | CCSD

International audience. Phenylketonuria is the most common inborn error of metabolism and causes irreversible mental retardation if left untreated. Its newborn screening was made possible by the technique of blood c...

Chargement des enrichissements...